GM, Stellantis shares fall after Trump’s auto tariff announcement

GM, Stellantis shares fall after Trump’s auto tariff announcement


The border wall is shown in a background as a semi-truck carrying Toyota trucks crosses a bridge after clearing U.S. Customs while entering the United States from Mexico along the border in San Diego, California, U.S., March 4, 2025. 

Mike Blake | Reuters

Auto stocks are digesting President Donald Trump’s announcement that he would place 25% tariffs on “all cars that are not made in the United States,” as well as certain automobile parts.

Trump’s administration had been telegraphing plans to put tariffs on the auto industry, but the impact of those moves and mechanism for enforcement are starting to take sharp. Trump said the tariffs would go into effect April 2.

General Motors stock was down about 6% in early trading Thursday, while Stellantis lost more than 1%. Tesla, however, was marginally higher while Ford Motor shares hovered around the flat line.

“In our coverage, for [original equipment manufacturers], Tesla and Ford appear to be the most shielded given location of vehicle assembly facilities although Ford does face incremental exposure on imported engines,” Deutsche Bank analysts wrote in a note Thursday. “GM has the most exposure to Mexico.”

Trump said Wednesday he would not put a tariff on vehicles that are built in the U.S.

The tariffs apply to imported passenger vehicles and light trucks, as well as key automobile parts including engines and transmissions, the White House said in a fact sheet.

Auto executive tells CNBC auto tariffs will drive auto industry into recession

Vehicles are made up of tens of thousands of parts, many of which cross back and forth over the U.S. border before a final product is completed.

Data and forecasting firm S&P Global Mobility reports there are on average 20,000 parts in a vehicle when it’s torn down to its nuts and bolts. Parts may originate in anywhere from 50 to 120 countries.

The firm also reports that 25 automakers on average produce 63,900 light-duty passenger vehicles in North America per day. A majority of those, roughly 65%, are assembled in the U.S., followed by 27% in Mexico and 8% in Canada.

Goldman Sachs analysts wrote Thursday that Trump’s 25% tariff could raise the price of imported cars by $5,000 to $15,000. If roughly 50% of parts in a U.S.-made car came from foreign sources, the tariff could raise the price of those cars by $3,000 to $8,000, they added.

The President had previously granted automakers a one-month tariff exemption for vehicles that comply with the United States-Mexico-Canada Agreement’s trade rules of origin.

— CNBC’s Michael Wayland and Michael Bloom contributed to this report.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More